Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease

Journal of the Formosan Medical Association

Volumn 105, Issue 9, 2006, Pages 743-752

  Wang, Chao Hung ^a   Leung, Ching Hsiang ^a   Liu, Sung Chen ^a   Chung, Cheng Ho ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Nonalcoholic fatty liver disease; Rosiglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEMOGLOBIN DETERMINATION; HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATIENT COMPLIANCE; STATISTICAL SIGNIFICANCE; TAIWAN; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 33749323970     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60202-3     Document Type: Article

References (38)

1. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical pathological severity. Gastroenterology 1999;116:1413-9.
2. Festi D, Colecchia A, Sacco T, et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004;5:27-42.
3. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5.
4. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-9.
5. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
6. Salt WB II. Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. J Insur Med 2004;36:27-41.
7. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24: 308-15.
8. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8.
9. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-9.
10. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802.
11. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-91.
12. Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 2002;10:1008-15.
13. Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003;52:1364-70.
14. Neuschwander-Terri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-r ligand rosiglitazone. Hepatology 2003;38:1008-17.
15. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-25.
16. Tolman KG, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003;7:367-79.
17. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002;25:815-21.
18. Rubin CJ, Schneider RL. Pioglitazone liver enzyme profiles is similar in placebo in US controlled clinical trials. Diabetes 2000-49:A123.
19. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for non alcoholic steatohepatitis. Hepatology 2004;39:188-96.
20. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28:412-9.
21. Dailey GE III, Noor MA, Park JS, et al. Glycemic control with glyburide/ metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double blind trial. Am J Med 2004;116: 223-9.
22. Day C, James O. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-5.
23. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-7.
24. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.J Clin Endocrinol Metab 2003; 88:1637-45.
25. Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-7
26. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000;23:1605-11.
27. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-7.
28. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000;22: 1395-409.
29. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004;116:230-5.
30. Miyazaki Y, Pipek R, Mandarino LJ, et al. Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients. Int J Obesity 2003;27:88-94.
31. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
32. Tonelli J, Li W, Kishore P, et al. Mechanism of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004;53:1621-9.
33. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
34. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflarnmatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35.
35. Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am 2004;33:417-29.
36. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
37. Quinn SF, Gosink BB. Characteristic sonographic signs of hepatic infiltration. Am J Roentgenol 1985;145: 753-5.
38. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002;17: 1136-43.